Latest B-cell chronic lymphocytic leukemia Stories
Having successfully Pioneered Robotic Surgery, Robert "Bob" Duggan Is Giving Hope to Cancer Patients Through His Innovative Biotech Company SUNNYVALE, Calif., May 7, 2014 /PRNewswire-iReach/
First full quarter after launch of IMBRUVICA(TM) net product revenue of $56.2 million SUNNYVALE, Calif., May 2, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that
FLINT, Mich., April 22, 2014 /PRNewswire-iReach/ -- The US Food and Drug Administration has announced the expanded approval of Arzerra(®) (ofatumumab) in combination with chlorambucil for
SUNNYVALE, Calif., April 21, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
LONDON, April 17, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S.
Transparency Market Research Report Added "Blood Disease Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database.
Emerging Therapies are Not Expected to Offer Improvements in Safety and Tolerability Attributes, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/
New submission based on positive Phase 3 data from the RESONATE(TM) trial RARITAN, N.J., April 8, 2014 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") today announced
SUNNYVALE, Calif., April 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S.
- In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
- In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.